UHS Stock Analysis — Universal Health Services
Sector: Healthcare
AI Verdict
UHS trades at 6.2x next year's earnings with negative EPS growth expected, so the low price reflects real skepticism about a turnaround despite the moat from regulatory barriers and local dominance.
Competitive Moat
Universal Health Services operates acute care hospitals and behavioral health facilities, benefiting from high barriers to entry due to regulatory complexity and the capital-intensive nature of hospital infrastructure. Its scale and diversified footprint across behavioral and acute care create local dominance in several markets, making patient and insurer relationships sticky.
Summary
UHS is trading at a deep discount after a 15.90% one-year drop and an RSI of 28.5, signaling extreme oversold territory.
Where It Stands
The stock is down -15.90% over the past year, trades at just 6.2x forward earnings versus the healthcare sector median of 22x, and its RSI of 28.5 is firmly in oversold territory.
Key Metrics
- RSI: 28.5 — Oversold
- Trailing P/E: 6.1x
- Forward P/E: 6.2x
- Earnings Growth: -0.0%
- Revenue Growth: +0.1%
- Market Cap: $8.8B
- Dividend Yield: 0.01%
- 1-Year Return: -15.90%
- 52-Week High: $246.33
- 52-Week Low: $140.08
Analyst Consensus
11 Buy · 14 Hold · 1 Sell (26 analysts)
Bull Case
At 6.2x forward earnings, UHS is extremely cheap for a hospital operator with 10.4% trailing revenue growth, suggesting the market is pricing in a worst-case scenario.
Bear Case
With forward EPS expected to shrink by -1.6% and a trailing P/E of 6.1x, even a modest re-rating to a 10x multiple would only lift the stock about 60%, but flat or falling earnings could keep it stuck in value trap territory.
Catalyst to Watch
Watch for quarterly earnings and any updates on reimbursement rates or labor costs—positive surprises could spark a sharp rebound from oversold levels.